Context Therapeutics Inc.
CNTXHealthcare|Biotechnology|US
$0.19
+0.01 (+2.98%)
DCF Value
$0.67
Tangible Book / Share
$0.40
Cash / Share
$0.45
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06515613 A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Platinum-resistant Ovarian Cancer, Testicular Cancer | P1 | Recruiting | 156 | Open-label | CTIM-76 |
| NCT07545122 A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Triple Negative Breast Cancer (TNBC), Colorectal Cancer | P1 | Recruiting | 162 | RCT, Open-label | CT-202 |
| NCT03909152 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer | P2 | Completed | 34 | Open-label | Onapristone ER, Onapristone ER + Anastrozole |
| NCT05618613 Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer | P1P2 | Terminated | 4 | Open-label | Elacestrant, Onapristone |
| NCT04738292 Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | ER-positive Breast Cancer, HER2-negative Breast Cancer | P2 | Terminated | 11 | Open-label | Onapristone, Fulvestrant |
| NCT04719273 Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma | P2 | Completed | 14 | Open-label | Extended-release Onapristone, Anastrozole |
| NCT06938711 A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Breast Cancer | P1P2 | Withdrawn | — | Open-label | Elacestrant, Onapristone |
| NCT06756035 CT-95 in Advanced Cancers Associated With Mesothelin Expression | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | P1 | Terminated | 19 | Open-label | CT-95 |
| NCT04872608 A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | Metastatic Breast Cancer, Unresectable Breast Cancer | P1 | Withdrawn | — | Open-label | Letrozole, Palbociclib, Onapristone ER |